Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Eloxx Pharmaceuticals, Inc.ELOX · healthcare
GradeNonecomputable_factors_below_threshold: 2 of 14 inputs computable; 7 are required
Reliability0.76 AUCfailure model, filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate0.60% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size bandunder $12.5M assetstotal assets $5.3M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningslate filer, thin data, degenerate inputs · fortress balance sheetnot computable: dilution, short runway, distress
Inputs computable2 of 14
Graded fromfilings received through Mar 17, 2026206 days before the rescan; every figure keyed to the SEC receipt date
Last close$14.642026-10-06; market equity $59.1M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$15$20JulAugSepOct$15.18
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Nov 21, 2012nonen/aQ1
Oct 21, 2014nonen/aQ2
Oct 21, 2016nonen/aQ1
Mar 21, 2018nonen/aQ2
Mar 21, 2026nonen/aQ1

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 17, 2026; the document on sec.gov.

—License Agreements—License Agreement between Eloxx and Almirall.” The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved.

Warnings [top]

Late filer. found 4 NT 10-K/Q filings in the last eight quarters
Thin data. 2 of 14 grade factors are computable; minimum is 7
Degenerate inputs. latest revenue or assets are at or below the $100,000 validity floor[1-2]
Fortress balance sheet. cash minus debt is 3,785,000 USD; Altman Z is not used[3-4]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
prior invested-capital observation is 1096 days earlier
Accruals rationot computable(6.6%)
prior assets observation is 1096 days earlier
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 97.2
Twelve-month failure probabilitynot computable0.07%
four consecutive discrete net-income quarters are required; found 4
Altman Z double-prime(209.70)[1,5-10](0.31)98.17562025-12-31
Net debt to EBITDAnot computable1.82x
EBITDA must exceed $100,000
Interest coveragenot computable(4.51x)
latest aligned inputs end 2017-12-31; latest annual assets end 2025-12-31
Current ratio0.31x[5-6]2.96x96.28392025-12-31
Growth and financing
Revenue growth, three-year compoundnot computable10.0%
four annual observations are required; found 3
Free cash flow growth, three-year compoundnot computable10.9%
four consecutive annual FCF observations are required; found 11
Reinvestment ratenot computable37.1%
NOPAT must exceed $100,000
Asset growth, three yearsnot computable2.1%
four consecutive annual observations are required
Net share issuance, one yearnot computable2.5%
prior share count is 1081 days earlier

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-06 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest monthnot computable8.0%missing required 12-1 monthly returns: 2026-06, 2026-05, 2026-04, 2026-03, 2026-02, 2026-01, 2025-12, 2025-11, 2025-10
Distance from 52-week high(27.6%)(31.4%)56closer to its high than 56 of 100 peers
EBIT to enterprise value(2,053.9%)(1.5%)1pricier than 99 of 100 peers
Free cash flow yield(52.1%)(1.0%)11pricier than 89 of 100 peers
Book value to price0.760.2879pricier than 21 of 100 peers
Sales to price0.000.310pricier than 100 of 100 peers
Composite equity issuance, five yearsnot computable20.3%five-year total-return history is required
Relative strength against the sector, log excess returnnot computable(0.14)missing required 12-1 monthly returns: 2026-06, 2026-05, 2026-04, 2026-03, 2026-02, 2026-01, 2025-12, 2025-11, 2025-10

Inputs: market equity $61.3M; EBIT -$6.4M; free cash flow -$31.9M; book equity $46.4M; sales $0; debt $1.0M; cash $62.0M[11].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zeron/a
Operating cash flow above zero-$6.3M✗ fail[12]
Return on assets improvedn/a[13]
Operating cash flow exceeds net income-$332,000✗ fail[12-13]
Long-term leverage felln/a[1,14]
Current ratio improvedn/a[5-6]
No new shares issuedn/a[15-16]
Gross margin improvedn/a
Asset turnover improvedn/a[2]
Cash, filings, liquidity
Cash and equivalentsn/a
Operating cash flow, four quartersn/a[17-21]
Months of runwaynot finite
the four latest operating-cash-flow quarters are not consecutive
Late filings, two years4
NT 10-K or NT 10-Q
Days since last periodic filing59
10-Q received Aug 11, 2026
Median daily dollar volume$531,799
63 sessions
Days since newest grade input206

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$5.3M2025-12-312026-03-1710-Kfiling · viewer · series
2revenueus-gaap:Revenues$02025-12-312026-03-1710-Kfiling · viewer · series
3cashus-gaap:CashAndCashEquivalentsAtCarryingValue$4.8M2025-12-312026-03-1710-Kfiling · viewer · series
4total debtus-gaap:LongTermDebt$1.0M2025-12-312026-03-1710-Kfiling · viewer · series
5current assetsus-gaap:AssetsCurrent$5.3M2025-12-312026-03-1710-Kfiling · viewer · series
6current liabilitiesus-gaap:LiabilitiesCurrent$17.2M2025-12-312026-03-1710-Kfiling · viewer · series
7retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$300.6M2025-12-312026-03-1710-Kfiling · viewer · series
8operating incomeus-gaap:OperatingIncomeLoss-$6.4M2025-12-312026-03-1710-Kfiling · viewer · series
9book equityus-gaap:StockholdersEquity-$11.9M2025-12-312026-03-1710-Kfiling · viewer · series
10liabilitiesus-gaap:Liabilities$17.2M2025-12-312026-03-1710-Kfiling · viewer · series
11shares outstandingdei:EntityCommonStockSharesOutstanding4,036,4592026-08-072026-08-1110-Qfiling · viewer · series
12operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$6.3M2025-12-312026-03-1710-Kfiling · viewer · series
13net incomeus-gaap:NetIncomeLoss-$6.0M2025-12-312026-03-1710-Kfiling · viewer · series
14long term debtus-gaap:LongTermDebtNoncurrent$02025-12-312026-03-1710-Kfiling · viewer · series
15shares outstandingdei:EntityCommonStockSharesOutstanding5,071,9352026-03-122026-03-1710-Kfiling · viewer · series
16shares outstandingdei:EntityCommonStockSharesOutstanding2,166,3562023-03-272023-03-3110-Kfiling · viewer · series
17operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$10.2M2026-06-302026-08-1110-Qfiling · viewer · series
18operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$5.5M2026-03-312026-05-0510-Qfiling · viewer · series
19operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$12.3M2023-09-302023-11-1310-Qfiling · viewer · series
20operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$8.9M2023-06-302023-08-1110-Qfiling · viewer · series
21operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$6.8M2023-03-312023-05-1210-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.